Takara Bio Inc. (TYO:4974)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Drug Discovery Company	40.32B	45.04B	43.51B	78.14B	67.70B
Total	40.32B	45.04B	43.51B	78.14B	67.70B

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Japan	14.14B	15.06B	15.43B	45.67B	34.08B
United States of America	12.26B	13.00B	12.97B	12.89B	10.19B
China	5.38B	8.52B	7.04B	10.80B	11.91B
Asia Excluding Japan and China	2.76B	2.86B	3.36B	3.55B	6.61B
Europe	5.41B	5.25B	4.50B	4.95B	4.67B
Others	372.00M	353.00M	205.00M	293.00M	244.00M
Total	40.32B	45.04B	43.50B	78.14B	67.70B

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 13, 2026

Data Sources Report a data error